Skip to main content
Premium Trial:

Request an Annual Quote

BioSeek Extends Merck Profiling Plan to 2012

NEW YORK (GenomeWeb News) – BioSeek has extended an agreement with Merck Serono, under which it will continue to profile compounds for the drug developer for another three years, BioSeek said today.

The new agreement extends a previous compound profiling plan from 2008, which had BioSeek using its BioMap platform to evaluate small molecule compounds and proteins in different therapeutic areas. The BioMap Systems use cell-based human disease models to develop information about potential drugs that companies can use to help choose and develop candidates.

The research agreement, which will last until 2012, includes studies that will support target differentiation, lead selection, and nomination of candidates that may be developed by Merck Serono, which is a division of Darmstadt, Germany-based Merck KGaA.

Financial terms of the agreement were not released.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.